Terms: = Leukemia AND PHF6, BORJ, 84295, ENSG00000156531, MGC14797 AND Clinical Outcome
4 results:
1. phf6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax.
Pinton A; Courtois L; Doublet C; Cabannes-Hamy A; Andrieu G; Smith C; Balducci E; Cieslak A; Touzart A; Simonin M; Lhéritier V; Huguet F; Balsat M; Dombret H; Rousselot P; Spicuglia S; Macintyre E; Boissel N; Asnafi V
Clin Cancer Res; 2024 Jan; 30(1):94-105. PubMed ID: 37889114
[TBL] [Abstract] [Full Text] [Related]
2. Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission strategies or relapse.
Onecha E; Rapado I; Luz Morales M; Carreño-Tarragona G; Martinez-Sanchez P; Gutierrez X; Sáchez Pina JM; Linares M; Gallardo M; Martinez-López J; Ayala R
Haematologica; 2021 Sep; 106(9):2325-2333. PubMed ID: 32732356
[TBL] [Abstract] [Full Text] [Related]
3. [Mutation of IL-7R in Adult Patients with T-cell Acute Lymphoblastic leukemia and Its clinical Significance].
Xiao LC; Li M; Ge Z; Gu Y; Zhou XL; Guo X; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug; 24(4):1014-8. PubMed ID: 27531766
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.
Patel JP; Gönen M; Figueroa ME; Fernandez H; Sun Z; Racevskis J; Van Vlierberghe P; Dolgalev I; Thomas S; Aminova O; Huberman K; Cheng J; Viale A; Socci ND; Heguy A; Cherry A; Vance G; Higgins RR; Ketterling RP; Gallagher RE; Litzow M; van den Brink MR; Lazarus HM; Rowe JM; Luger S; Ferrando A; Paietta E; Tallman MS; Melnick A; Abdel-Wahab O; Levine RL
N Engl J Med; 2012 Mar; 366(12):1079-89. PubMed ID: 22417203
[TBL] [Abstract] [Full Text] [Related]
